866-997-4948(US-Canada Toll Free)

Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Feb 2017

Category :

Pharmaceutical

No. of Pages : 189 Pages

Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) Pipeline Review, H1 2017, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape.

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis (Scleroderma) Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 12, 4, 22 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Sclerosis (Scleroderma) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Systemic Sclerosis (Scleroderma) - Overview 8
Systemic Sclerosis (Scleroderma) - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Systemic Sclerosis (Scleroderma) - Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 23
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development 31
Allergan Plc 31
AnaMar AB 31
Angion Biomedica Corp 32
arGentis Pharmaceuticals LLC 32
Bayer AG 33
Biogen Inc 33
BiOrion Technologies BV 34
BLR Bio LLC 34
Boehringer Ingelheim GmbH 35
Bristol-Myers Squibb Company 35
Covis Pharmaceuticals Inc 36
CSL Ltd 36
Cumberland Pharmaceuticals Inc 37
F. Hoffmann-La Roche Ltd 37
Fibrocell Science Inc 38
GenKyoTex SA 38
Gilead Sciences Inc 39
GlaxoSmithKline Plc 39
iBio Inc 40
Inventiva 40
Kadmon Corp LLC 41
MedImmune LLC 41
miRagen Therapeutics Inc 42
Patagonia Pharmaceuticals LLC 42
PDX Pharmaceuticals LLC 43
Peptinov SAS 43
ProMetic Life Sciences Inc 44
Ribomic Inc 44
Samumed LLC 45
Sanofi 45
Stemline Therapeutics Inc 46
viDA Therapeutics Inc 46
VivaCell Biotechnology Espana SL 47
Systemic Sclerosis (Scleroderma) - Drug Profiles 48
abatacept - Drug Profile 48
acALY-18 - Drug Profile 55
ambrisentan - Drug Profile 56
ANG-3070 - Drug Profile 58
ARG-201 - Drug Profile 59
belimumab - Drug Profile 61
BLR-200 - Drug Profile 68
BOT-191 - Drug Profile 69
C-1889 - Drug Profile 70
C-82 - Drug Profile 72
CM-101 - Drug Profile 73
dimethyl fumarate DR - Drug Profile 74
factor XIII (human) - Drug Profile 79
FCX-013 - Drug Profile 80
GKT-831 - Drug Profile 81
GSK-2330811 - Drug Profile 84
IBIOCFB-03 - Drug Profile 85
ifetroban sodium - Drug Profile 87
IVA-337 - Drug Profile 89
JBT-101 - Drug Profile 91
KD-025 - Drug Profile 97
M-10 - Drug Profile 102
MEDI-7734 - Drug Profile 103
miRNA-29 - Drug Profile 104
Monoclonal Antibodies to Antagonize IL-3RA for Autoimmune Disorders - Drug Profile 105
MRG-201 - Drug Profile 106
nintedanib - Drug Profile 108
nitroglycerin - Drug Profile 119
onabotulinumtoxinA - Drug Profile 121
PAT-048 - Drug Profile 126
PATS-03 - Drug Profile 127
PBI-4050 - Drug Profile 128
PDX-002 - Drug Profile 135
PPV-06 - Drug Profile 136
RBM-006 - Drug Profile 137
riociguat - Drug Profile 138
rituximab biosimilar - Drug Profile 144
RP-182 - Drug Profile 145
SAR-100842 - Drug Profile 146
SAR-156597 - Drug Profile 147
SAR-317461 - Drug Profile 148
SM-04755 - Drug Profile 149
Small Molecule to Inhibit NFkB for Autoimmune Disorders, Melanoma and Inflammation - Drug Profile 150
Small Molecules to Antagonize 5-HT2B for Fibrosis - Drug Profile 151
Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile 152
terguride - Drug Profile 153
tocilizumab - Drug Profile 154
TRX-101 - Drug Profile 164
VCE-0048 - Drug Profile 165
VEDA-1209 - Drug Profile 166
VTI-1000 Series - Drug Profile 167
Wnt-001 - Drug Profile 168
Systemic Sclerosis (Scleroderma) - Dormant Projects 169
Systemic Sclerosis (Scleroderma) - Discontinued Products 171
Systemic Sclerosis (Scleroderma) - Product Development Milestones 172
Featured News & Press Releases 172
Appendix 185
Methodology 185
Coverage 185
Secondary Research 185
Primary Research 185
Expert Panel Validation 185
Contact Us 185
Disclaimer 186

List of Tables
Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Allergan Plc, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by AnaMar AB, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Angion Biomedica Corp, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals LLC, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Bayer AG, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Biogen Inc, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by BiOrion Technologies BV, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by BLR Bio LLC, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Company, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Covis Pharmaceuticals Inc, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by CSL Ltd, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Cumberland Pharmaceuticals Inc, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Fibrocell Science Inc, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by GenKyoTex SA, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Gilead Sciences Inc, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline Plc, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by iBio Inc, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Inventiva, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Kadmon Corp LLC, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by MedImmune LLC, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by miRagen Therapeutics Inc, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Patagonia Pharmaceuticals LLC, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by PDX Pharmaceuticals LLC, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Peptinov SAS, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by ProMetic Life Sciences Inc, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Ribomic Inc, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Samumed LLC, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Sanofi, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Stemline Therapeutics Inc, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by viDA Therapeutics Inc, H1 2017
Systemic Sclerosis (Scleroderma) - Pipeline by VivaCell Biotechnology Espana SL, H1 2017
Systemic Sclerosis (Scleroderma) - Dormant Projects, H1 2017
Systemic Sclerosis (Scleroderma) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Systemic Sclerosis (Scleroderma) - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *